. 2021 Feb 9;314(1):1–15. doi: 10.1007/s00403-021-02190-6

Table 2.

Summary of cutaneous adverse reactions in current USA/UK/Brazil/South Africa based COVID Clinical Trials

Sponsor	Vaccine	Phase trial	Reported cutaneous adverse reactions (non-injection site related) in vaccine groups
AstraZenica	ChAdOx1 nCoV-19	I,II,III	Rosacea flare, Pruritus; cellulitis
Moderna	mRNA-1273	I/II/III	-1 instance of transient urticaria on both legs 5 days after receiving first dose of vaccine 25mcg vaccine; -1 instance of a maculopapular rash -2 instances of hypersensitivity reaction to previously injected facial dermal filler (deemed serious adverse events) -1 instance of angioedema of lips in subject with history of lip dermal filler injection
Pfizer-BioNTech	BNT162b2	I,II,III	Hypersensitivity-related adverse events 137 participants, 0.63%

Sponsor

Vaccine

Phase trial

Reported cutaneous adverse reactions (non-injection site related) in vaccine groups

AstraZenica

ChAdOx1 nCoV-19

I,II,III

Rosacea flare, Pruritus; cellulitis

Moderna

mRNA-1273

I/II/III

-1 instance of transient urticaria on both legs 5 days after receiving first dose of vaccine 25mcg vaccine;

-1 instance of a maculopapular rash

-2 instances of hypersensitivity reaction to previously injected facial dermal filler (deemed serious adverse events)

-1 instance of angioedema of lips in subject with history of lip dermal filler injection

Pfizer-BioNTech

BNT162b2

I,II,III

Hypersensitivity-related adverse events 137 participants, 0.63%